Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Virax Biolabs Group Ltd. has announced the resignation of CTO Mark Ternouth and his departure from the Board for personal reasons, effective immediately. Dr. Nigel McCracken, previously COO, has been appointed to fill the vacant Board position. McCracken boasts an impressive background with leadership roles in various biopharmaceutical companies and academic credentials in Clinical Pharmacology and Biochemical Toxicology.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.
